Drugs / Netakimab
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06640517 | Aug 2024 → Jun 2026 overdue | psoriasis | Biocad | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07008547 | Jul 2024 → Mar 2025 | psoriasis | SPH-BIOCAD (HK) Limited | Completed | No outcome recorded |
| Phase 3 | NCT07277179 | Mar 2023 → Jul 2024 | ankylosing spondylitis | SPH-BIOCAD (HK) Limited | Completed | No outcome recorded |
| Phase 3 | NCT03390101 | Dec 2017 → Jul 2018 | psoriasis | Biocad | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Netakimab | “Netakimab (NTK), an original humanized anti-interleukin-17 monoclonal antibody, showed therapeutic efficacy in moderate-to-severe plaque psoriasis in a phase 2 clinical study.” PMID 34060012 ↗ May 2021 |
| Known as | NTK | “Netakimab (NTK), an original humanized anti-interleukin-17 monoclonal antibody, showed therapeutic efficacy in moderate-to-severe plaque psoriasis in a phase 2 clinical study.” PMID 34060012 ↗ May 2021 |
| Modality | Monoclonal antibody | — CHEMBL6068083 ↗ |
| Route | Subcutaneous | “netakimab will be administered subcutaneously with induction once a week for the first three weeks, then once every 4 weeks” NCT06640517 ↗ |